Interferon-based Simeprevir Therapy for Pediatric Patients with Chronic Hepatitis C Viral Infection

Interferon-based simeprevir therapy showed high efficacy and tolerability in children with genotype 1 hepatitis C virus infection. While direct-acting antivirals (DAAs) therapy are undergoing study in children, this regimen is considered an available therapeutic option for selected patients in count...

Full description

Bibliographic Details
Main Authors: Mitsuyoshi Suzuki, Kei Minowa, Hitoshi Tajiri
Format: Article
Language:English
Published: Elsevier 2018-09-01
Series:Annals of Hepatology
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S1665268119302522
_version_ 1818671891114622976
author Mitsuyoshi Suzuki
Kei Minowa
Hitoshi Tajiri
author_facet Mitsuyoshi Suzuki
Kei Minowa
Hitoshi Tajiri
author_sort Mitsuyoshi Suzuki
collection DOAJ
description Interferon-based simeprevir therapy showed high efficacy and tolerability in children with genotype 1 hepatitis C virus infection. While direct-acting antivirals (DAAs) therapy are undergoing study in children, this regimen is considered an available therapeutic option for selected patients in countries where DAAs have not yet been approved.
first_indexed 2024-12-17T07:31:12Z
format Article
id doaj.art-c859fa52d41847428e3bdee86435551f
institution Directory Open Access Journal
issn 1665-2681
language English
last_indexed 2024-12-17T07:31:12Z
publishDate 2018-09-01
publisher Elsevier
record_format Article
series Annals of Hepatology
spelling doaj.art-c859fa52d41847428e3bdee86435551f2022-12-21T21:58:30ZengElsevierAnnals of Hepatology1665-26812018-09-01175756758Interferon-based Simeprevir Therapy for Pediatric Patients with Chronic Hepatitis C Viral InfectionMitsuyoshi Suzuki0Kei Minowa1Hitoshi Tajiri2Department of Pediatrics, Juntendo University Faculty of Medicine, Bunkyo-ku, Tokyo, Japan; Correspondence and reprint request:Department of Pediatrics, Juntendo University Faculty of Medicine, Bunkyo-ku, Tokyo, JapanDepartment of Pediatrics, Osaka General Medical Center, Sumiyoshi-ku, Osaka, JapanInterferon-based simeprevir therapy showed high efficacy and tolerability in children with genotype 1 hepatitis C virus infection. While direct-acting antivirals (DAAs) therapy are undergoing study in children, this regimen is considered an available therapeutic option for selected patients in countries where DAAs have not yet been approved.http://www.sciencedirect.com/science/article/pii/S1665268119302522PeginterferonRibavirinDirect-acting antiviralsHyperbilirubinemiaShorter treatment time
spellingShingle Mitsuyoshi Suzuki
Kei Minowa
Hitoshi Tajiri
Interferon-based Simeprevir Therapy for Pediatric Patients with Chronic Hepatitis C Viral Infection
Annals of Hepatology
Peginterferon
Ribavirin
Direct-acting antivirals
Hyperbilirubinemia
Shorter treatment time
title Interferon-based Simeprevir Therapy for Pediatric Patients with Chronic Hepatitis C Viral Infection
title_full Interferon-based Simeprevir Therapy for Pediatric Patients with Chronic Hepatitis C Viral Infection
title_fullStr Interferon-based Simeprevir Therapy for Pediatric Patients with Chronic Hepatitis C Viral Infection
title_full_unstemmed Interferon-based Simeprevir Therapy for Pediatric Patients with Chronic Hepatitis C Viral Infection
title_short Interferon-based Simeprevir Therapy for Pediatric Patients with Chronic Hepatitis C Viral Infection
title_sort interferon based simeprevir therapy for pediatric patients with chronic hepatitis c viral infection
topic Peginterferon
Ribavirin
Direct-acting antivirals
Hyperbilirubinemia
Shorter treatment time
url http://www.sciencedirect.com/science/article/pii/S1665268119302522
work_keys_str_mv AT mitsuyoshisuzuki interferonbasedsimeprevirtherapyforpediatricpatientswithchronichepatitiscviralinfection
AT keiminowa interferonbasedsimeprevirtherapyforpediatricpatientswithchronichepatitiscviralinfection
AT hitoshitajiri interferonbasedsimeprevirtherapyforpediatricpatientswithchronichepatitiscviralinfection